JP5891233B2 - ７−（［１，２，３］トリアゾール−４−イル）−ピロロ［２，３−ｂ］ピラジン誘導体 - Google Patents

７−（［１，２，３］トリアゾール−４−イル）−ピロロ［２，３−ｂ］ピラジン誘導体 Download PDF

Info

Publication number
JP5891233B2
JP5891233B2 JP2013535296A JP2013535296A JP5891233B2 JP 5891233 B2 JP5891233 B2 JP 5891233B2 JP 2013535296 A JP2013535296 A JP 2013535296A JP 2013535296 A JP2013535296 A JP 2013535296A JP 5891233 B2 JP5891233 B2 JP 5891233B2
Authority
JP
Japan
Prior art keywords
compounds
compound
cancer
formula
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013535296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540783A (ja
Inventor
ドルシュ，ディーター
ヴッヘラー−プリートカー，マルガリータ
ミュラー，トーマス，ヨット．，ヨット．
メルクル，オイゲン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2013540783A publication Critical patent/JP2013540783A/ja
Application granted granted Critical
Publication of JP5891233B2 publication Critical patent/JP5891233B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013535296A 2010-11-01 2011-10-12 ７−（［１，２，３］トリアゾール−４−イル）−ピロロ［２，３−ｂ］ピラジン誘導体 Expired - Fee Related JP5891233B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010049877.7 2010-11-01
DE102010049877A DE102010049877A1 (de) 2010-11-01 2010-11-01 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
PCT/EP2011/005126 WO2012059171A1 (fr) 2010-11-01 2011-10-12 Dérivés de 7-([1,2,3]triazol-4-yl)-pyrrolo[2,3-b]pyrazine

Publications (2)

Publication Number Publication Date
JP2013540783A JP2013540783A (ja) 2013-11-07
JP5891233B2 true JP5891233B2 (ja) 2016-03-22

Family

ID=44862924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013535296A Expired - Fee Related JP5891233B2 (ja) 2010-11-01 2011-10-12 ７−（［１，２，３］トリアゾール−４−イル）−ピロロ［２，３−ｂ］ピラジン誘導体

Country Status (11)

Country Link
US (1) US8865715B2 (fr)
EP (1) EP2635581B1 (fr)
JP (1) JP5891233B2 (fr)
CN (1) CN103168042B (fr)
AR (1) AR083670A1 (fr)
AU (1) AU2011325479B8 (fr)
CA (1) CA2816363C (fr)
DE (1) DE102010049877A1 (fr)
ES (1) ES2535607T3 (fr)
IL (1) IL226094A0 (fr)
WO (1) WO2012059171A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
RU2015114936A (ru) * 2012-10-16 2016-12-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы серин/треонинкиназы
CA2936551A1 (fr) 2014-01-24 2015-07-30 Confluence Life Sciences, Inc. Pyrrolopyridines et pyrrolopyrazines substituees pour traiter le cancer ou les maladies inflammatoires
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
AU2015320675B2 (en) 2014-09-26 2018-10-18 Gilead Sciences, Inc. Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CA2973597A1 (fr) 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Inhibiteurs d'itk heterocycliques pour traiter l'inflammation et le cancer
WO2017106556A1 (fr) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Composés inhibiteurs de kinases se liant à tank
US10138219B2 (en) 2016-02-19 2018-11-27 Pmv Pharmaceuticals Methods and compounds for restoring mutant p53 function
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
US11027260B2 (en) 2019-02-13 2021-06-08 Uchicago Argonne, Llc Low pressure nanowire membrane for catalytic reactions and methods of making and using the same
CA3152160A1 (fr) 2019-09-23 2021-04-01 Binh Vu Derives de 1h-indol-2-propynyle et compositions pharmaceutiques connexes utiles pour retablir la fonction du gene p53 mutant
US11938124B2 (en) 2020-06-24 2024-03-26 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
TWI339206B (en) * 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
EP1696907B1 (fr) * 2003-10-03 2013-04-17 The Ohio State University Research Foundation Inhibiteurs de signalisation pdk-1/akt
EP2239262A3 (fr) 2004-07-27 2011-10-19 SGX Pharmaceuticals, Inc. Composés hétérocycliques annelés comme modulateurs de kinases
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN101052629A (zh) * 2004-08-02 2007-10-10 Osi制药公司 芳基－氨基取代的吡咯并嘧啶多激酶抑制化合物
EP1814882A1 (fr) * 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines et pyrazolopyrazines convenant inhibiteurs de proteines-kinases
CA2601983A1 (fr) 2005-04-06 2006-10-12 Astrazeneca Ab Heterocycles substitues et leur utilisation en tant qu'inhibiteurs de la chk1, de la pdk1 et de la pak
JP5642963B2 (ja) 2006-06-30 2014-12-17 スネシス ファーマシューティカルズ，インコーポレイティド ピリジノニルｐｄｋ１阻害剤
BRPI0720563A2 (pt) 2006-12-22 2014-02-04 Novartis Ag Quinazolinas para inibição de pdk1
CA2679694A1 (fr) 2007-03-13 2008-09-18 Merck & Co., Inc. Inhibiteurs de janus kinases et/ou proteine kinase-1 dependant de la 3-phosphoinositide
AU2008266883B2 (en) 2007-06-20 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2211620B1 (fr) 2007-10-25 2013-12-25 Merck Sharp & Dohme Corp. PYRROLO[2,3-b]PYRIDINES SUBSTITUES EN POSITION3 PAR UN PYRAZINE EN TANT QU`INHIBITEURS DE JANUS KINASE POUR LE TRAITEMENT DES MALADIES DE CANCER
ES2554375T3 (es) 2008-11-25 2015-12-18 University Of Rochester Inhibidores de las MLK y métodos de uso
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
CN102471345A (zh) * 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡嗪抑制剂
DE102009060175A1 (de) * 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen

Also Published As

Publication number Publication date
CN103168042A (zh) 2013-06-19
DE102010049877A1 (de) 2012-05-03
CA2816363C (fr) 2019-03-05
EP2635581A1 (fr) 2013-09-11
AU2011325479B2 (en) 2015-04-09
US8865715B2 (en) 2014-10-21
JP2013540783A (ja) 2013-11-07
CA2816363A1 (fr) 2012-05-10
IL226094A0 (en) 2013-06-27
EP2635581B1 (fr) 2015-02-25
ES2535607T3 (es) 2015-05-13
AU2011325479A8 (en) 2015-05-14
AU2011325479B8 (en) 2015-05-14
AU2011325479A1 (en) 2013-05-02
CN103168042B (zh) 2015-10-21
AR083670A1 (es) 2013-03-13
US20130217951A1 (en) 2013-08-22
WO2012059171A1 (fr) 2012-05-10

Similar Documents

Publication Publication Date Title
JP5891233B2 (ja) ７−（［１，２，３］トリアゾール−４−イル）−ピロロ［２，３−ｂ］ピラジン誘導体
JP5731481B2 (ja) ３−（１，２，３−トリアゾール−４−イル）ピロロ［２，３−ｂ］ピリジン誘導体
US9725446B2 (en) 7-azaindole derivatives
JP5411849B2 (ja) ６−（ピロロピリジニル）−ピリミジン−２−イルアミン誘導体ならびに癌およびａｉｄｓの処置のためのその使用
JP6074364B2 (ja) ５−（１，２，３−トリアゾール−４−イル）−７ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体
JP5524864B2 (ja) ４−（ピロロ［２，３−ｃ］ピリジン−３−イル）ピリミジン−２−アミン誘導体
JP5718359B2 (ja) ピロロ［２，３−ｂ］ピラジン−７−イルピリミジン化合物
JP2013544264A (ja) ＰＤＫ１阻害剤としての３−ヘタリール置換ピロロ［２，３−ｂ］ピリジン誘導体
JP6027609B2 (ja) 癌疾患の処置に適する７−アザインドール誘導体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160222

R150 Certificate of patent or registration of utility model

Ref document number: 5891233

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees